{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:20:53Z","timestamp":1793305253361,"version":"4.5.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Novel strategies are needed for the treatment of acute ischemic stroke when revascularization therapies are not clinically appropriate or are unsuccessful. rKLK1 (recombinant human tissue kallikrein-1), a bradykinin-producing enzyme, offers a promising potential solution. In animal studies of acute stroke, there is a marked 36-fold increase in bradykinin B2 receptor on brain endothelial cells of the ischemic region. Due to this environment, rKLK1-generated bradykinin will exert a potent local vasodilation and increase brain perfusion via 3 synergistic signaling pathways downstream to the B2 receptor. Because of its preferential effect on ischemic tissue, systemic adverse effects such as hypotension are avoided with proper dosing. In addition, with initial vasodilation through recruitment of preexisting collaterals, rKLK1 promotes long-term benefit of brain perfusion by promoting new collateral formation. With an extended course of therapy for weeks after acute ischemic stroke, these multifaceted effects may also reduce the risk of stroke recurrence. A prior phase II trial demonstrated a favorable impact on clinical outcomes and recurrent strokes, particularly among patients who were not eligible for mechanical thrombectomy. A phase II\/III trial has launched in this population, though opportunities for combination revascularization therapies deserve further investigation.<\/jats:p>","DOI":"10.1161\/strokeaha.124.048858","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:01:47Z","timestamp":1736139707000},"page":"745-753","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Recombinant Human Tissue Kallikrein-1 for Treating Acute Ischemic Stroke and Preventing Recurrence"],"prefix":"10.1161","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0418-6917","authenticated-orcid":true,"given":"Scott E.","family":"Kasner","sequence":"first","affiliation":[{"name":"University of Pennsylvania School of Medicine, Division of Vascular Neurology, Philadelphia (S.E.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2734-5132","authenticated-orcid":true,"given":"Philip M.","family":"Bath","sequence":"additional","affiliation":[{"name":"Stroke Trials Unit, University of Nottingham, United Kingdom (P.M.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6269-1543","authenticated-orcid":true,"given":"Michael D.","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary and Foothills Medical Centre, Alberta, Canada (M.D.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4716-3734","authenticated-orcid":true,"given":"John J.","family":"Volpi","sequence":"additional","affiliation":[{"name":"Houston Methodist, Department of Neurology, Houston, TX (J.J.V.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Giuffre","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Calgary, Alberta, Canada (M.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorianne","family":"Masuoka","sequence":"additional","affiliation":[{"name":"DiaMedica Therapeutics, Minnetonka, MN (L.M., D.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4377-808X","authenticated-orcid":true,"given":"David","family":"Wambeke","sequence":"additional","affiliation":[{"name":"DiaMedica Therapeutics, Minnetonka, MN (L.M., D.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-9205","authenticated-orcid":true,"given":"Paolo R.","family":"Madeddu","sequence":"additional","affiliation":[{"name":"Experimental Cardiovascular Medicine, University of Bristol, United Kingdom (P.R.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/17474930211065917"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13724"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2015.03.006"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-80508-0_18"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-073X.2007.00216.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030240"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.bbrc.2013.03.001","article-title":"Human tissue kallikreins 3 and 5 can act as plasminogen activator releasing active plasmin.","volume":"433","author":"de Souza LR","year":"2013","unstructured":"de Souza LR, Melo MP, Paschoalin T, Carmona AK, Kondo M, Hirata IY, Blaber M, Tersariol I, Takatsuka J, Juliano MA, et al. Human tissue kallikreins 3 and 5 can act as plasminogen activator releasing active plasmin. Biochem Biophys Res Commun. 2013;433:333\u2013337. doi: https:\/\/doi.org\/10.1016\/j.bbrc.2013.03.001","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/159646"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01287.2004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00168"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0444"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418821918"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2018.01.003"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22404"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600096"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198553"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0162-3109(99)00116-2"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134543"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2008.01.099"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2012-0069"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000250235.80253.e9"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.2004.028571"},{"key":"e_1_3_2_24_2","first-page":"679","article-title":"Angiogenesis therapy with human tissue kallikrein for the treatment of ischemic diseases.","volume":"97","author":"Emanueli C","year":"2004","unstructured":"Emanueli C, Madeddu P. Angiogenesis therapy with human tissue kallikrein for the treatment of ischemic diseases. Arch Mal Coeur Vaiss. 2004;97:679\u2013687.","journal-title":"Arch Mal Coeur Vaiss"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.20.11.2379"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.103.1.125"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.38.1.136"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc0302.102142"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000027104.33206.c8"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.179952"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2022.02936"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000142051.36244.83"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.037869"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03003-6"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.025494"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.024582"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.253419"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/23969873211057421"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.026389"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.1526"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/156146"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m109493200"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.03.032"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.17712\/nsj.2016.2.20150581"},{"key":"e_1_3_2_45_2","unstructured":"Kasner S Bath P Volpi J. Randomized double-blind placebo-controlled adaptive design study to evaluate Dm199 for the treatment of acute ischemic stroke within a 24-hour treatment window (ReMEDy2 Trial). In: International Stroke Conference (ISC). Phoenix Arizona: Diamedica Therapeutics; 2024."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1033"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520943452"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00403"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000518"},{"key":"e_1_3_2_50_2","first-page":"1009","article-title":"Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction.","volume":"19","author":"Wang YX","year":"2015","unstructured":"Wang YX, Chen Y, Zhang CH, Li CH, Dong Z, Zhao SN, Wang Z, Zhang FF, Tong XG, Wang JH, et al. Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction. Eur Rev Med Pharmacol Sci. 2015;19:1009\u20131012.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000499"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1500669"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.104026"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.94.3.517"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1159\/000362666"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.102.18.2190"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.027465"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.118117"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.55.11.1475"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/STROKEAHA.124.048858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T17:11:30Z","timestamp":1758561090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.124.048858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1161\/STROKEAHA.124.048858"],"URL":"https:\/\/doi.org\/10.1161\/strokeaha.124.048858","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2025-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}